Chinese biotech sector will face US threats
Chinese biotech firms have gained a respite as progress on the US Biosecure Act has stalled
You must be signed in to read this analysis
In this article
- Early innovation
- Room for progress
- Western worries
- The Biosecure Act
- Impact on China
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
